510(k) SUMMARY

NOV 1 0 2011

ActiViews's CT-Guide Needle Guidance System

Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared

ActiViews Ltd. 7 Nahum Haat St. Haifa 31905 Israel

Phone: (972) 48551002 Facsimile: (972) 48551003

Contact Person: Yuval Zuk

Date Prepared: October 14, 2011

Name of Device and Name/Address of Sponsor

CT-Guide Needle Guidance System ActiViews Ltd 7 Nahum Haat St. Haifa 31905 Israel

Common or Usual Name/ Classification Name

Computed Tomography X-ray System Accessory

Predicate Device

ActiViews Ltd.'s CT-Guide Needle Guidance System (K110812)

Intended Use/Indications for Use

The CT-Guide is a stereotactic accessory for Computed Tomography ("CT") systems. The CT-Guide displays an interventional instrument on a computer monitor that also displays a CT-based model of the target organ(s).

The CT-Guide is intended to be used in clinical interventions in the lung, where CT is currently used for visualizing such procedures.

Technological Characteristics

The CT-Guide System is comprised of four main components: (1) the ActiSensor, a disposable video camera that is mounted onto a holder, which is clipped to a needle; (2) the ActiSticker, a disposable pad, which provides visual and radio-opaque reference markers; (3) a workstation that contains a dedicated computer; and (4) accompanying computer software.

Purpose of the Special 510(k) Notice

The purpose of this Special 510(k) notice is to address hardware and software design modifications to the cleared CT-Guide Needle Guidance System cleared via K110812. The device modifications include:


- Modification of the ActiSticker design to include 3 entry holes instead of 1 entry hole
 in the previous version of the system, as well as to the system software to support
 this change in the ActiSticker.
- Various software modifications implemented to provide improved user interface and additional information to the user during the procedure.
- System level changes that include the following: new version of the computer, the
 cart, the monitor and a change in the operating system. The computer, cart and the
 monitor have been updated to a newer version and meet or exceed the predefined
 specifications in the originally cleared version of the device.

Performance Data

The modified CT-Guide Needle Guidance System was tested for its performance and accuracy through several bench tests conducted on a custom phantom setup. All results were satisfactory and met the predefined specifications. The CT-Guide modified software was validated and tested. In addition, the CT-Guide system was retested for electromagnetic compatibility and electrical safety per IEC 60601-1 and IEC 60601-1-2. In all instances, the CT-Guide functioned as intended and the testing results observed were as expected.

Substantial Equivalence

The modified CT-Guide Needle Guidance System has the same intended use and indications, and similar principles of operation, and technological characteristics as the previously cleared CT-Guide Needle Guidance System. The minor differences in the modified CT-Guide Needle Guidance System's technological characteristics do not raise any new questions of safety or effectiveness. Performance data demonstrates that the modified CT-Guide Needle Guidance System is as safe and effective as the predicate CT-Guide Needle Guidance System. Thus, the modified CT-Guide Needle Guidance System is substantially equivalent to its identified predicate device.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

ActiViews, Ltd. % John J. Smith, M.D., J.D. Regulatory Counsel Hogans Lovells, US LLP 555 13th Street, NW WASHINGTON DC 20004

NOV 1 0 2011

Re: K113063

Trade/Device Name: CT-Guide Needle Guidance System

Regulation Number: #1 CFR 892.1750

Regulation Name: Computed tomography x-ray system

Regulatory Class: II Product Code: JAK Dated: October 14, 2011 Received: October 14, 2011

Dear Dr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely Yours,

Mary S. Pastel, Sc.D.

Director

Division of Radiological Devices Office of In Vitro Diagnostic Device

Mary Startel

Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

Indications for Use

STO(K) Number (II	KHOWH).		•
Device Name:	CT-Guide Needle	Guidance System	
Indications for Use	э:		
	interventional instru	-	nography ("CT") systems. The CT- nonitor that also displays a CT-based
The CT-Guide is in for visualizing such		in clinical interventions	in the lung, where CT is currently used
			·
Prescription Use _ (Per 21 C.F.R. 80		AND/OR	Over-The-Counter Use (Per 21 C.F.R. 807 Subpart C)
(PLEASE DO NO	T WRITE BELOW T	HIS LINE-CONTINUE	ON ANOTHER PAGE IF NEEDED)
C	concurrence of CDR	H, Office of In Vitro Dia	agnostic Devices (OIVD)
Office of In Vitro	,	gical Devices Evaluation and Safe	
510(k) Number	K 113063		
	•		